FollowMyHealth Patient Portal

Nancy Lee Bartlett, MD

Professor, Medicine
Division of Oncology
Koman Chair in Medical Oncology

Specialty Areas

Medical Oncology
Oncology
Hematologic Malignancies
Lymphoma

Board Certifications

Internal Medicine
Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Non-Hodgkin's and Hodgkin's lymphoma, chronic lymphocytic leukemia, hematologic malignancies

  • Maps & Directions
  • Education
  • Publication & Research

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110
Phone: 314-747-7222

Suite: B
Floor: 7
Office Phone: 314-747-1171
Fax: 314-747-5123

Education

Education

Fellowship: Medical Oncology, Stanford University, California 1993
Chief Residency: Medicine, University of California, San Francisco, California 1990
Residency: Medicine, University of California, San Francisco, California 1989
Medical Degree: Washington University School of Medicine, St. Louis, Missouri 1986
M.S.: Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 1979
B.A.: Chemical Engineering, Stanford University, California 1978

Publication & Research

Publication & Research

Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.
Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM
Cancer. 2017 Sep 13; doi: 10.1002/cncr.30979.

PMID:
    28902390
    [PubMed - as supplied by publisher]
Related citations


Lack of Prognostic Impact of MyD88 L265P Mutation for DLBCL Patients Undergoing Autologous Stem Cell Transplantation.
Lee YS, Liu J, Fricano KA, Webb EM, Toolsie DR, Jones S, Rhoads JA, Vij R, Cashen AF, Abboud CN, Westervelt P, Bartlett NL, Dipersio JF, Kreisel FH, Lim KH
Biol Blood Marrow Transplant. 2017 Aug 25; pii: S1083-8791(17)30657-2. doi: 10.1016/j.bbmt.2017.08.022.

PMID:
    28847710
    [PubMed - as supplied by publisher]
Related citations


A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.
Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston ND, Phelps MA, Bartlett NL, Blum KA
Clin Lymphoma Myeloma Leuk. 2017 Jun; 17(6)347-353. doi: 10.1016/j.clml.2017.05.008.

PMID:
    28622959
    [PubMed - in process]
Related citations


Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study.
Goyal S, Oak E, Luo J, Cashen AF, Carson K, Fehniger T, DiPersio J, Bartlett NL, Wagner-Johnston ND
Leuk Lymphoma. 2017 Jun 9; 1-6. doi: 10.1080/10428194.2017.1330954.

PMID:
    28597723
    [PubMed - as supplied by publisher]
Related citations


Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, Friedberg JW, van der Jagt RH, LaCasce AS, Joyce R, Ganjoo KN, Bartlett NL, Lemieux B, VanderWalde A, Herst J, Szer J, Bar MH, Cabanillas F, Dodds AJ, Montgomery PG, Pressnail B, Ellis T, Smith MR, Leonard JP
Br J Haematol. 2017 Jul; 178(2)250-256. doi: 10.1111/bjh.14667.

PMID:
    28419413
    [PubMed - indexed for MEDLINE]
Related citations


Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Jaslowski A, Smith SE, Cheson BD, Hsi E, Leonard JP
Lancet Haematol. 2017 Apr; 4(4)e176-e182. doi: 10.1016/S2352-3026(17)30028-5.

PMID:
    28314699
    [PubMed - in process]
Related citations


Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY
Mol Ther. 2017 Jan 4; 25(1)285-295. doi: 10.1016/j.ymthe.2016.10.020.

PMID:
    28129122
    [PubMed - indexed for MEDLINE]
Related citations


Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.
Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, Fronick CC, Fulton RS, Kreisel F, Cashen AF, Carson KR, Berrien-Elliott MM, Bartlett NL, Griffith M, Griffith OL, Fehniger TA
Blood. 2017 Jan 26; 129(4)473-483. doi: 10.1182/blood-2016-07-729954.

PMID:
    28064239
    [PubMed - indexed for MEDLINE]
Related citations


Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.
Diefenbach CS, Connors JM, Friedberg JW, Leonard JP, Kahl BS, Little RF, Baizer L, Evens AM, Hoppe RT, Kelly KM, Persky DO, Younes A, Kostakaglu L, Bartlett NL
J Natl Cancer Inst. 2017 Apr; 109(4)pii: djw249. doi: 10.1093/jnci/djw249.

PMID:
    28040700
    [PubMed - indexed for MEDLINE]
Related citations


Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED
Leuk Lymphoma. 2017 Jul; 58(7)1607-1616. doi: 10.1080/10428194.2016.1256481.

PMID:
    27868471
    [PubMed - in process]
Related citations


Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, Smith SM, Czuczman M, Davids MS, Levine E, Lewis LD, Smith SE, Bartlett NL, Leonard JP, Cheson BD
Blood. 2016 Nov 24; 128(21)2510-2516.

PMID:
    27697771
    [PubMed - indexed for MEDLINE]
Related citations


Magnetic resonance image guided radiation therapy for primary splenic diffuse large B-cell lymphoma: A teaching case.
Fischer-Valuck BW, Green O, Mazur T, Li H, Chundury A, Rao YJ, Bartlett NL, Mutic S, Huang J
Pract Radiat Oncol. 2017 Jan - Feb; 7(1)e23-e26. doi: 10.1016/j.prro.2016.06.004.

PMID:
    27531255
    [PubMed - indexed for MEDLINE]
Related citations


Fine-Tuning the Treatment of Hodgkin's Lymphoma.
Bartlett NL
N Engl J Med. 2016 Jun 23; 374(25)2490-2. doi: 10.1056/NEJMe1604026.

PMID:
    27332908
    [PubMed - indexed for MEDLINE]
Related citations


Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
Cheah CY, Bröckelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA
Am J Hematol. 2016 Sep; 91(9)894-9. doi: 10.1002/ajh.24429.

PMID:
    27222367
    [PubMed - indexed for MEDLINE]
Related citations


A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
Oak E, Bartlett NL
Expert Opin Drug Saf. 2016 Jun; 15(6)875-82. doi: 10.1080/14740338.2016.1179277.

PMID:
    27139729
    [PubMed - indexed for MEDLINE]
Related citations


Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma.
Chen R, Allibone S, Bartlett NL, Brice P, Chen A, Pose K, Rich L, Bonthapally V, Garfin PM, Fanale M
Onco Targets Ther. 2016; 92027-34. doi: 10.2147/OTT.S96175.

PMID:
    27103829
    [PubMed]
Related citations


US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW
J Clin Oncol. 2016 Jun 10; 34(17)2020-7. doi: 10.1200/JCO.2015.63.1119.

PMID:
    27069074
    [PubMed - indexed for MEDLINE]
Related citations


Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, Bokstein F, Bovi JA, Solhjem MC, Mehta MP
J Clin Oncol. 2016 May 10; 34(14)1620-5. doi: 10.1200/JCO.2015.64.8634.

PMID:
    27022122
    [PubMed - indexed for MEDLINE]
Related citations


A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Flinn IW, Bartlett NL, Blum KA, Ardeshna KM, LaCasce AS, Flowers CR, Shustov AR, Thress KS, Mitchell P, Zheng F, Skolnik JM, Friedberg JW
Eur J Cancer. 2016 Feb; 5411-7. doi: 10.1016/j.ejca.2015.10.005.

PMID:
    26707592
    [PubMed - indexed for MEDLINE]
Related citations


Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M, HELIOS investigators.
Lancet Oncol. 2016 Feb; 17(2)200-211. doi: 10.1016/S1470-2045(15)00465-9.

PMID:
    26655421
    [PubMed - indexed for MEDLINE]
Related citations